Ascendis Pharma A/S (NASDAQ:ASND) just released its latest second-quarter results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.8% to hit €339m. Ascendis Pharma also reported a statutory profit of €2.83, which was an impressive 104% above what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Taking into account the latest results, the current consensus from Ascendis Pharma's 16 analysts is for revenues of €1.36b in 2026. This would reflect a huge 30% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to leap 28% to €14.42. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.34b and earnings per share (EPS) of €13.27 in 2026. So the consensus seems to have become somewhat more optimistic on Ascendis Pharma's earnings potential following these results.

The consensus price target was unchanged at US$310, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Ascendis Pharma at US$361 per share, while the most bearish prices it at US$261. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Ascendis Pharma'shistorical trends, as the 69% annualised revenue growth to the end of 2026 is roughly in line with the 62% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 23% annually. So although Ascendis Pharma is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Ascendis Pharma following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$310, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Ascendis Pharma. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Ascendis Pharma going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.